Abstract: Objective To observe the therapeutic effects and its safety of entecavir in treatment of hepatitis
B patients with liver failure. Methods Total of 56 hepatitis B patients with liver failure from January 2014
to December 2014 in Third Peoples’ Hospital of Jiujiang were selected and randomly divided into treatment
group and control group, 28 cases in each group. The treatment group were treated with entecavir 0.5 mg/d
orally on the basis of basic supportive therapy. The control group were only given basic medical therapy.
The survival rate, liver function, prothrombin activity (PTA) and negative rate of HBV DNA at 48 weeks
after treatment were observed and compared. Results The survival rate of treatment group and control
group were 71.4% and 42.9%, respectively, and the difference was statistically significant (χ 2 = 4.67, P =
0.031). After 48 weeks’ treatment, the levels of PTA and TBil in treatment group were (73 ± 10)% and (55 ±
13) µmol/L, which in control group were (61 ± 10)% and (89 ± 22) µmol/L, respectively, the differences
were statistically significant (t = 0.003, -11.44; P = 0.031, 0.000). The negative rate of HBV DNA in
treatment group and control group were 80.0% and 41.7%, respectively, the difference was statistically
significant (χ 2 = 4.89, P = 0.027). Conclusion Entecavir is safe and can improve the survival rate and liver
function in hepatitis B patients with liver failure.